Back to top
more

Thermo Fisher Scientific (TMO)

(Delayed Data from NYSE)

$596.92 USD

596.92
2,138,161

+3.13 (0.53%)

Updated Oct 11, 2024 04:00 PM ET

After-Market: $596.52 -0.40 (-0.07%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (96 out of 250)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

National Vision's (EYE) Q3 Earnings Top Estimates, View Raised

National Vision's (EYE) third-quarter performance reflects strong growth in core business segments.

Option Care Health (BIOS) Q3 Earnings Meet, Revenues Top

Albeit Option Care Health (BIOS) is yet to reap material benefits from its merger-related synergies, the reporting of a positive gross margin in third-quarter results is encouraging for investors.

DENTSPLY SIRONA (XRAY) Beats on Q3 Earnings, Ups '19 View

DENTSPLY SIRONA (XRAY) gains from solid segmental contributions in Q3.

Globus Medical (GMED) Q3 Earnings Meet Mark, Revenue View Up

Globus Medical (GMED) reports robust top-line numbers for the third quarter on segmental strength.

Hologic's (HOLX) Q4 Earnings Meet, Revenues Top Estimates

Hologic (HOLX) exhibits robust fourth-quarter growth fueled by strong segmental performance.

Cardinal Health (CAH) Q1 Earnings & Revenues Beat Estimates

Cardinal Health (CAH) Q1 results benefit revenue growth and strong segmental performance. However, contraction in gross margin remains a concern.

AmerisourceBergen (ABC) Q4 Earnings & Revenues Beat Estimates

AmerisourceBergen's (ABC) Q4 earnings benefit from higher revenues, segmental growth and strong fiscal 2020 outlook.

Insulet (PODD) Beats on Q3 Earnings, Ups '19 Revenue View

Insulet's (PODD) year-over-year improvement in Q3 revenues on the solid uptake of Omnipod system both in the United States and across international markets looks promising.

OPKO Health (OPK) Q3 Earnings Miss Estimates, Revenues Beat

OPKO Health (OPK) third-quarter results benefit from higher Product revenues and RAYALDEE prescription growth.

CVS Health (CVS) Beats on Q3 Earnings, Raises '19 EPS Guidance

CVS Health's (CVS) strong year-over-year growth in the top line is aided by a robust performance at the Pharmacy Services segment.

Phibro's (PAHC) Q1 Earnings & Revenues Fall Y/Y, Margins Down

Phibro (PAHC) exhibits a dismal first-quarter performance on a decline in revenues at core business segments.

HMS Holdings (HMSY) Q3 Earnings Top Estimates, Revenues Miss

HMS Holdings' (HMSY) Q3 earnings benefit from higher revenues at Analytical Services unit and strong 2019 outlook.

Avanos (AVNS) Earnings and Revenues Miss Estimates in Q3

Avanos (AVNS) third-quarter results benefit from higher revenues and strong segmental performance.

Zacks.com featured highlights include: SYNNEX, Thermo Fisher Scientific, Allstate, Intel and Target

Zacks.com featured highlights include: SYNNEX, Thermo Fisher Scientific, Allstate, Intel and Target

Inogen's (INGN) Q3 Earnings and Revenues Beat Estimates

Softness in domestic and international business-to-business revenues impact Inogen's (INGN) Q3 results.

DaVita (DVA) Earnings and Revenues Beat Estimates in Q3

DaVita (DVA) raises guidance for 2019 following impressive Q3 results.

STERIS' (STE) Q2 Earnings Surpass Estimates, FY20 View Up

STERIS (STE) witnesses solid revenue growth across each of its operating segments in the second quarter of fiscal 2020.

Zimmer Biomet (ZBH) Q3 Earnings Top, Operating Margin Falls

Zimmer Biomet (ZBH) gains from strong sales growth across all geographies and most operating segments in Q3.

Hill-Rom's (HRC) Q4 Earnings Beat on Strong Global Sales

Internationally, Asia Pacific, Latin America and EMEA registers strong revenue growth for Hill-Rom (HRC).

Allscripts (MDRX) Q3 Earnings Beat Estimates, Improve Y/Y

Allscripts (MDRX) third-quarter results gain from growth in bookings and solid segmental performance. Contraction in both gross and operating margins remains a woe.

Luminex (LMNX) Reports Q3 Loss, Misses Revenue Estimates

Luminex's (LMNX) Q3 earnings benefit from higher revenues and solid performance across System Sales, Consumable Sales and Service Revenues. However, gross margin contraction remains a woe.

Myriad Genetics (MYGN) Lags Q1 Earnings and Revenue Estimates

Myriad Genetics (MYGN) observes a decline in Hereditary Cancer, GeneSight, Vectra as well as Other testing revenues in Q1.

Henry Schein (HSIC) Q3 Earnings Top Estimates, Revenues Lag

Henry Schein (HSIC) registers solid performance across its key operating businesses in Q3.

Becton, Dickinson (BDX) Beats on Q4 Earnings and Revenues

Becton, Dickinson (BDX) gains from solid segmental contributions in Q4.

Tandem Diabetes (TNDM) Q3 Loss Narrows Y/Y, Sales Improve

Tandem Diabetes (TNDM) exhibits a robust performance in the third quarter of 2019, fueled by strong domestic demand.